📰 Nasdaq Huma News
Page 4 - Nasdaq Huma News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Huma. Real-time updates on events, politics, business and more.
May 26, 2022
Equities research analysts expect Humacyte, Inc. (NASDAQ:HUMA – Get Rating) to report sales of $260,000.00 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Humacyte’s earnings. The lowest sales estimate is $130,000.00 and the highest is $400,000.00. The company is expected to issue its next quarterly earnings report […]
May 16, 2022
Humacyte (NASDAQ:HUMA – Get Rating) was downgraded by investment analysts at Piper Sandler from an “overweight” rating to an “underweight” rating in a research report issued to clients and investors on Sunday, The Fly reports. Separately, Zacks Investment Research lowered Humacyte from a “buy” rating to a “hold” rating in a research report on Saturday, […]
May 16, 2022
Humacyte (NASDAQ:HUMA – Get Rating) announced its quarterly earnings data on Friday. The company reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.02, MarketWatch Earnings reports. NASDAQ:HUMA opened at $5.37 on Monday. The stock’s fifty day moving average price is $6.60 and its two-hundred day moving average price […]
April 5, 2022
Humacyte (NASDAQ:HUMA – Get Rating) and Cullinan Oncology (NASDAQ:CGEM – Get Rating) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, profitability, institutional ownership and risk. Profitability This table compares Humacyte and Cullinan Oncology’s net margins, […]
April 1, 2022
Humacyte (NASDAQ:HUMA – Get Rating) issued its quarterly earnings results on Tuesday. The company reported $0.41 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.61, MarketWatch Earnings reports. NASDAQ:HUMA opened at $7.06 on Friday. The business has a 50 day moving average price of $5.76 and a […]
March 31, 2022
Humacyte (NASDAQ:HUMA – Get Rating) had its target price decreased by equities researchers at Piper Sandler from $17.00 to $10.00 in a research note issued on Tuesday, The Fly reports. Piper Sandler’s price target suggests a potential upside of 37.55% from the stock’s previous close. Separately, Zacks Investment Research upgraded Humacyte from a “hold” rating […]
March 28, 2022
Wall Street analysts expect Humacyte, Inc. (NASDAQ:HUMA – Get Rating) to announce ($0.19) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Humacyte’s earnings. The firm is expected to issue its next earnings results before the market opens on Monday, January 1st. On average, analysts expect […]
March 25, 2022
Wall Street analysts predict that Humacyte, Inc. (NASDAQ:HUMA – Get Rating) will post sales of $260,000.00 for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for Humacyte’s earnings, with the lowest sales estimate coming in at $120,000.00 and the highest estimate coming in at $400,000.00. The firm is scheduled to issue […]
March 16, 2022
Shares of Humacyte, Inc. (NASDAQ:HUMA – Get Rating) saw strong trading volume on Wednesday . 20,816 shares were traded during trading, a decline of 95% from the previous session’s volume of 411,191 shares.The stock last traded at $5.68 and had previously closed at $5.67. Separately, Zacks Investment Research raised Humacyte from a “hold” rating to […]
March 4, 2022
Wall Street brokerages forecast that Humacyte, Inc. (NASDAQ:HUMA – Get Rating) will report sales of $260,000.00 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have made estimates for Humacyte’s earnings, with estimates ranging from $120,000.00 to $400,000.00. The business is scheduled to announce its next earnings results on Friday, March 4th. […]